Volume 1.15 | Apr 30

Prostate Cell News 1.15, April 30, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


FDA Approval of New Prostate Treatment Shows Promise of Cancer Immunotherapy
The U.S. Food and Drug Administration approval of Dendreon’s Provenge® (sipuleucel-T) to treat certain men with advanced prostate cancer marks a significant advance in the development of biological therapy for cancer treatment. [International Society for Biological Therapy of Cancer Press Release]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies



AACR: Metformin Brakes Prostate Tumor Growth
The commonly prescribed anti-diabetes drug metformin appears to improve the ability of bicalutamide (Casodex) to slow proliferation in hormone-resistant prostate cancer cell lines, researchers reported. [MedPage Today Press Release]

AACR: Vegetable Compound Sensitizes Prostate Cancer
A substance found in cruciferous vegetables can make resistant prostate cancer cells sensitive to taxane therapy with docetaxel (Taxotere), laboratory researchers said. [MedPage Today Press Release]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies



Discovery of a Novel Unfolded Protein Response Phenotype of Cancer Stem/Progenitor Cells from the Bone Marrow of Breast Cancer Patients
The results suggest the presence of a previously not recognized stress resistant disseminated tumor cell population that combines stem/progenitor attributes with an unfolded protein response phenotype. [J Proteome Res]

SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In Vitro and In Vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis
In the current study, researchers have examined the efficacy of a Src/Abl kinase inhibitor SKI-606 (Bosutinib) for its effect on prostate cancer growth and skeletal metastasis. [Mol Cancer Ther]

A Probasin Promoter, Conditionally Replicating Adenovirus that Expresses the Sodium Iodide Symporter (NIS) for Radiovirotherapy of Prostate Cancer
Researchers have extended the use of NIS-mediated radioiodine therapy to other types of cancer and transferred and expressed the NIS gene into prostate, colon and breast cancer cells using adenoviral vectors. [Gene Ther]

Differential Regulation of Insulin-Like Growth Factor-I Receptor Gene Expression by Wild Type and Mutant Androgen Receptor in Prostate Cancer Cells
To investigate the differential effects of wild type and mutant androgen receptor on insulin-like growth factor-I receptor levels, researchers employed a series of isogenic prostate-derived cell lines and human xenografts. [Mol Cell Endocrinol]

Normal and Malignant Epithelial Cells with Stem-Like Properties Have an Extended G2 Cell Cycle Phase that is Associated with Apoptotic Resistance
The aim of this study was to investigate the mechanisms of resistance to apoptosis-inducing agents of cells with stem-like properties in both normal and malignant human epithelia. [BMC Cancer]

Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer
Researchers developed a model for predicting prostate cancer risk from standard biomarkers, rs198977 genotype, and rs198977-kallikrein-related peptidase 2 interaction. [Cancer Prev Res]


Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy
The primary objective of this study was to determine whether statin use is associated with improved clinical outcomes in patients treated with radiotherapy for prostate cancer. [J Clin Oncol]

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation
This was an exploratory analysis of a trial of intermittent androgen deprivation in men with biochemical relapse to establish first cycle characteristics prognostic for progression to castration-resistant prostate cancer and death. [J Clin Oncol]

Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication
Researchers previously reported that a panel of four kallikrein forms in blood-total, free, and intact prostate-specific antigen (PSA) and kallikrein-related peptidase 2-can reduce unnecessary biopsy in previously unscreened men with elevated total PSA. Researchers aimed to replicate prior findings in a large, independent, representative, population-based cohort. [J Clin Oncol]


Cancer Treatment Centers of America Utilizes Calypso Real-Time Tracking to Help Reduce Side Effects for Prostate Cancer Radiation Patients
Calypso Medical Technologies, Inc. announced that with the installation of the Calypso® System at the Cancer Treatment Centers of America (CTCA) at Southwestern Regional Medical Center in Tulsa, Oklahoma, Calypso’s real-time tumor tracking technology is now available at all CTCA centers nationwide. [Calypso Medical Technologies, Inc. Press Release]

Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease
Protox Therapeutics Inc. announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. [Protox Therapeutics Inc. Press Release]

Cells Programmed to Cure and Even Prevent Cancer
The Institute for Research in Immunology and Cancer of the Université de Montréal is proud to announce the launch of the very first ribonucleic acid engineering laboratory in Canada. [Institute for Research in Immunology and Cancer Press Release]

CIRM Awards $28 Million to Answer Fundamental Questions in Stem Cell Biology
At a meeting at the City of Hope, the governing board of the California Institute for Regenerative Medicine, the state stem cell agency created by Proposition 71, approved funding $28 million to support 16 Basic Biology II Awards that answer fundamental questions about stem cell biology and one Leadership Award. [California Institute for Regenerative Medicine Press Release]


Gubernatorial Candidates Talk Ways to Boost Bioscience
Five gubernatorial candidates offered their prescriptions for creating a healthier climate for Minnesota’s biotech industry that included lower taxes, higher government spending, and faith in science over ideology. [Minnesota, United States]

Request for Information (RFI): Priorities for the NIH Adherence Research Network (NOT-OD-10-078) [National Institutes of Health, United States]

Waivers for Conflicts of Interest for the May 7, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Food and Drug Administration, United States]

FDA Announces Draft Revised Guidance on Transparency and Advisory Committees [Food and Drug Administration, United States]

Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members’ Financial Interest Information and Waivers; Availability (Docket No. FDA-2002-D-0094) [Food and Drug Administration, United States]


American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us